Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis AG with three other
companies in this sector in UNITED STATES :
sales of $51.75 billion
of which 76%
Merck & Co. , Inc.
of which 89%
was Merck Pharmaceutical), and
of which 46%
Novartis AG reported sales of $48.62 billion
December of 2019.
decrease of 8.5%
versus 2018, when the company's sales were $53.17 billion.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Novartis AG had sales
of $53.33 billion.
Contributing to the drop in overall sales was the 1.3% decline
in Sandoz, from $9.86 billion to $9.73 billion.
However, these declines were partially offset by the increase in sales of
Innovative Medicines (up 8.1% to $37.71 billion)